R&D in pharmaceuticals
The science and medicine sector is growing exponentially as we search for innovative solutions to new diseases and illnesses. R&D is a hot topic in this space!
Who qualifies for R&D in pharmaceuticals?
Your organisation could operate within any part of the drug development life-cycle, although consideration of contractual arrangements will be key to establishing your eligibility and which scheme can apply for R&D tax credits.
Find out more about R&D tax relief and its value to companies operating within all sub-components of the life science industry here.
Innovations in medical devices have equally transformative outcomes for mankind.
What types of pharmaceutical projects may qualify for R&D tax credits?
Drug discovery
Running candidate compound screening, characterisation processes, DMPK research and onward collaboration to assess efficacy, toxicity and pharmacokinetic information.
Medical research
Seeking out new medicines, medical procedures, medical devices or improvements to those that exist.
Ancillary developments
From carrier products (creams, liquids, lotions, sprays) to packaging components, sterilisation efficacy & stability preservation.
Development life cycles
The creation of bespoke software capabilities or resolving problems with system uncertainty to manage, control and process all aspects of drug development.
What will an R&D pharmaceutical team look like?
Scientists and technicians specialising in your discipline. Bespoke IT commissions could feature to support the clinical trials process, which may involve qualifying development work in software.
What might qualifying projects for R&D in pharmaceuticals involve?
- Experimental testing methodologies
- Finding out how to predict outcomes of therapeutic agents
- Developing new compounds to duplicate the effects of patented drugs without infringing patented traits
- Seeking approaches to incorporate compounds into new formulations that were not previously possible
- Modelling and simulation of chemical modifications
- Overcoming issues with absorption
- Developing models to scale up experimental methodologies
.jpg)
.jpg)
.jpg)
Expert R&D tax advice
Let’s talk R&D
Book a call
